Argentum has a proven track record of leveraging its proprietary portfolio selection process to identify dubious and anti-competitive evergreening patents that improperly delay patient access to generic medication. For instance, Argentum has challenged several patents via Inter Partes Review (IPR) that have ultimately been held invalid or unpatentable, including products generating USD$ billions per year in revenue, including:
Zytiga (abiraterone acetate)
Restasis (cyclosporine emulsion)
All of these drugs that now are open for generic competition years ahead of the original patent expiry.
To that end, Argentum has a particular interest in utilizing Authorized Generics to accelerate entry of high-quality generics into the market at the earliest possible date.
What are Authorized Generics?
An Authorized Generic (AG) is the brand prescription product sold in private label packaging at generic prices. The AG is identical to the brand in every way; meaning that unlike standard generics, it contains the exact same active and inactive ingredients as the brand. And with the same shape, color, size, smell, taste and mouth feel, the AG provides a patient with the same overall experience as the brand product.
In partnership with a manufacturer, Argentum current has one AG selling on the market today: an authorized generic form of Restasis (cyclosporine emulsion) for dry eye disease.
Argentum Pharmaceuticals LLC
301 East Hopkins Avenue, Suite 201 Aspen, CO 81611